Cost-Effectiveness of Tirzepatide vs Semaglutide: How to Compare Value

Head-to-Head Cost Analysis: Brand-Name Pricing

Comparing the sticker prices of tirzepatide and semaglutide provides a starting point but not the full picture. At current list prices, both medications fall in the premium tier of pharmaceutical pricing, reflecting their position as highly effective treatments for conditions that affect millions of patients.

Semaglutide is available as Wegovy (weight management, $1,349-$1,430/month list) and Ozempic (diabetes, $968-$1,023/month list). Tirzepatide is marketed as Zepbound (weight management, $1,059/month list) and Mounjaro (diabetes, $1,023-$1,069/month list). At list price, Zepbound is notably less expensive than Wegovy for the weight management indication, while Mounjaro and Ozempic are closely priced for diabetes.

However, list prices are increasingly disconnected from what patients and insurers actually pay. Manufacturer rebates, pharmacy benefit manager negotiations, and savings card programs create a wide gap between the list price and the net cost. The effective cost to insured patients is heavily influenced by their specific plan's formulary placement, preferred pharmacy network, and copay structure. For a detailed breakdown of semaglutide-specific pricing, see our semaglutide cost guide.

Cost Per Pound Lost: A Framework for Comparison

One commonly used metric for comparing obesity treatments is the cost per pound (or kilogram) of weight lost. This metric attempts to normalize the comparison by accounting for differences in efficacy between medications. While useful as a rough framework, it has significant limitations that patients should understand.

Based on clinical trial data, tirzepatide at the highest dose (15 mg) produces approximately 20-22% body weight loss, while semaglutide at 2.4 mg produces approximately 15-17%. For a 250-pound patient, this translates to roughly 50-55 pounds lost on tirzepatide versus 37-42 pounds on semaglutide. If both medications cost the same monthly amount, tirzepatide would offer a lower cost per pound lost simply by producing more total weight loss.

In practice, however, per-pound calculations change dramatically based on individual response. Not every patient achieves the average trial result. A patient who responds exceptionally well to semaglutide (losing 20%+) would achieve a lower cost per pound than a patient who has only an average response to tirzepatide. Additionally, the dose required to achieve optimal results varies: some patients achieve their goals at lower (and less expensive) doses of either medication, while others require the maximum dose.

Insurance Coverage Differences: Tirzepatide vs Semaglutide

Insurance coverage is often the most important practical factor in determining which medication is more affordable for a specific patient. Semaglutide has been on the market longer and currently enjoys broader formulary coverage across both commercial and government plans. Tirzepatide coverage is expanding but remains more variable.

For type 2 diabetes indications, both Ozempic and Mounjaro are widely covered by commercial insurance plans, though formulary tier placement and preferred status vary by plan. Some plans have placed one medication as preferred over the other, resulting in lower copays for the preferred option. Patients should check their specific formulary rather than assuming equivalent coverage.

For weight management indications, the coverage picture is more complex. Wegovy has been available since 2021 and has been added to an increasing number of commercial formularies, though many plans still exclude it. Zepbound, approved for weight management in late 2023, is newer and coverage adoption is still evolving. Some plans cover Wegovy but not yet Zepbound, while others have added Zepbound at a preferred tier due to its lower list price. For patients without coverage, see our guide on accessing semaglutide without insurance.

Prior authorization requirements also differ between medications and plans. Some insurers require documented failure of lifestyle intervention before approving either medication, while others have specific BMI thresholds or comorbidity requirements. Understanding these requirements before starting treatment can save months of frustration and ensure patients access the medication with the best coverage pathway available to them.

Compounded Pricing Comparison: Tirzepatide vs Semaglutide

For patients paying out of pocket, compounded versions of both medications offer significantly lower prices than brand-name options. However, the pricing dynamics differ between the two molecules, and understanding these differences helps patients make informed decisions about which compounded option offers better value.

Compounded semaglutide is generally less expensive than compounded tirzepatide. Typical monthly costs for compounded semaglutide range from $199-$345, while compounded tirzepatide typically runs $350-$550 per month, depending on dose and program structure. The price difference reflects the higher raw material cost and more complex formulation requirements for tirzepatide, which is a dual-agonist molecule.

When comparing compounded options on a cost-per-pound basis, the calculation becomes nuanced. If a patient achieves 20% weight loss on compounded tirzepatide at $450/month versus 14% on compounded semaglutide at $275/month, the per-pound cost may be similar despite the monthly price difference. The key variable is individual response, which cannot be predicted with certainty before starting treatment.

Patients evaluating compounded options should ensure they are comparing equivalent programs. Some lower-priced compounded options may not include clinical oversight, regular provider check-ins, or dosing adjustment support, while more comprehensive programs bundle these services into a higher monthly fee. The total value of a program extends beyond the medication itself. For a deeper dive into compounded options, see our article on compounded vs brand-name semaglutide.

Long-Term Value Calculation: Beyond Monthly Cost

The true cost-effectiveness of GLP-1 therapy cannot be assessed by looking at monthly medication prices alone. A comprehensive value assessment must account for the downstream health economic effects of sustained weight loss and metabolic improvement over years, not just the upfront cost of the medication over months.

Health economic modeling studies have examined both semaglutide and tirzepatide in the context of long-term value. These models consistently show that the healthcare cost savings from reduced obesity-related comorbidities, including type 2 diabetes prevention, cardiovascular event reduction, reduced orthopedic interventions, and decreased cancer risk, offset a substantial portion of the medication cost over 5-10 year time horizons.

For individual patients, the long-term value calculation should consider several factors. How much weight loss is needed to achieve meaningful health improvement? What comorbidities are present that might improve or resolve with weight loss? What is the expected duration of treatment? And what is the cost of not treating obesity, including both direct medical costs and indirect costs like reduced work productivity, disability, and quality of life impact?

Patients with more comorbidities and higher baseline health risk generally derive greater long-term value from GLP-1 therapy, as the health improvements translate into larger cost offsets. A patient who avoids a type 2 diabetes diagnosis through timely obesity treatment saves an estimated $9,600 per year in direct diabetes-related healthcare costs, which quickly compounds to exceed the cost of the GLP-1 medication itself. Learn about the full range of metabolic improvements in our GLP-1 health benefits beyond weight loss article.

Which Is More Cost-Effective by Scenario?

Rather than declaring a single winner, it is more useful to examine which medication offers better value in specific patient scenarios. The optimal choice depends on the intersection of clinical factors, insurance coverage, and financial constraints.

The most cost-effective approach for any individual patient is one that balances medication efficacy, affordability, adherence sustainability, and comprehensive clinical support. A medication that works well but cannot be afforded consistently is less cost-effective than a slightly less potent option that the patient can maintain long-term. For a full clinical comparison, see our guide on tirzepatide vs semaglutide.

How to Make Your Decision: A Practical Framework

Deciding between tirzepatide and semaglutide based on cost-effectiveness requires gathering specific, current information about your individual situation. Generalizations and outdated price comparisons are not reliable guides for personal decision-making.

Start by verifying your insurance coverage for both medications in both the diabetes and weight management categories. Call the number on your insurance card and ask specifically about formulary status, tier placement, prior authorization requirements, and estimated copay for each medication. This information changes frequently, so verification should be recent.

Next, explore manufacturer savings programs and determine your eligibility. Both Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide) offer savings programs that can dramatically reduce out-of-pocket costs for eligible patients. Compare the net cost after savings programs are applied, not the list price.

If considering compounded options, request detailed pricing that includes all fees (medication, consultations, supplies, shipping) to compare total monthly costs. Verify pharmacy credentials and included services. The lowest headline price is not always the best value when services and safety are considered.

Finally, discuss the clinical factors with your healthcare provider. If one medication is expected to work meaningfully better for your specific profile based on comorbidities, metabolic markers, or prior treatment history, the additional efficacy may justify a higher price. Conversely, if both medications are expected to work similarly well for you, the less expensive option with better coverage is the clear choice. For more on how these medications compare clinically, visit our GLP-1 real-world effectiveness analysis.